SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: biostruggle who wrote (1954)3/28/2002 8:37:42 AM
From: Harold Engstrom  Read Replies (1) | Respond to of 10345
 
FWIW, I think that UCB is a household name. Even here in the USA.

Also, the analyst might consider that with another drug to sell UCB might increase its sales force.



To: biostruggle who wrote (1954)3/28/2002 9:27:10 AM
From: Robohogs  Respond to of 10345
 
Zytec marketing rights were handed over to Pfizer in U.S. - speaks to UCB's strength (or lack thereof) in U.S. UCB handles them in Europe. Do not know if UCB kept co-promote in the U.S. I will say that Sepracor almost has as much penetration into general practice doctors as UCB does. And ELN already had neurology field well-covered. Oh well.

Jon


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News